Related Experiment Video
Updated: Aug 14, 2025

Author Spotlight: Elucidating the Pathways of TFH Cell Differentiation in Acute LCMV Challenges
Published on: April 26, 2024
Biological Features of CD5+ CD19+ B1 Cell and Natural IgM (VH4-34) in Chronic Lymphocytic Leukemia vs. Multiple
Shaghayegh Pezeshki1, Mir Hadi Jazayeri2, Bahram Chahardouli3
1Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. shaghayegh.pezeshki@yahoo.com.
Insights
Chronic lymphocytic leukemia (CLL) involves increased CD5+ B cells, while multiple sclerosis (MS) shows a decrease. Researchers propose using natural antibodies from CLL patients to treat MS.
Area of Science:
- Immunology
- Hematology
- Neurology
Background:
- Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of mature CD5+ B cells, often referred to as B1-CLL.
- B1 cells possess anti-inflammatory properties, including natural IgM (nIgM) production and modulation of cytokines like TGFβ, crucial for tissue homeostasis.
Purpose of the Study:
- To investigate B cell immunophenotypes and natural IgM (nIgM) levels in patients with CLL and multiple sclerosis (MS) compared to healthy controls.
- To explore a novel therapeutic strategy for MS by leveraging the unique antibody profile of CLL patients.
Main Methods:
- Flow cytometry was employed to immunophenotype B cells and their subpopulations in peripheral blood from CLL, MS, and control groups.
- Real-time RT-PCR was used to quantify the VH4-34 gene copy number, a marker associated with natural IgM production.
Main Results:
- CLL patients exhibited significantly higher proportions of CD5+ B lymphocytes compared to controls.
- MS patients showed a significantly lower proportion of CD5+ B cells than controls.
- CLL patients had significantly elevated VH4-34 gene copy numbers, whereas MS patients had significantly reduced levels compared to controls.
Conclusions:
- The distinct B cell profiles and natural antibody levels in CLL and MS suggest a potential therapeutic avenue.
- A novel treatment approach for MS is proposed, involving the extraction and administration of natural antibodies from CLL patients' sera.
Abstract:
Chronic lymphocytic leukemia (CLL) is the clonal expansion of mature CD5+ B cells and the most common lymphoproliferative disease in adults (B1-CLL). B1 cells' anti-inflammatory effects include the production of natural IgM (nIgM) by the spleen and bone marrow, decreased inflammatory cytokines as a primary response to maintaining tissue homeostasis, and enhanced release of transforming growth factor β (TGFβ). We used the flow cytometry technique in peripheral blood from patients with CLL and multiple sclerosis (MS) to immunophenotype B cells and their subpopulations. Whole blood from CLL and MS patients, as well as healthy controls, was used to detect nIgM using the VH4-34 gene copy number and real-time RT-PCR. We found that the proportion of CD5+ B cells was significantly lower in MS patients than in the control group and that CD5+ B lymphocytes were significantly higher in CLL patients than in the control group. Compared to the control group, CLL patients had significantly higher levels of the VH4-34 gene copy number. On the contrary, MS patients had significantly lower VH4-34 gene copy number levels compared to the control group. As the number of antibodies in CLL patients increases due to the high number of B1 cells, we propose a new way to treat MS by extracting this natural antibody from the sera of CLL patients and injecting it into MS patients.
More Related Videos
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

